Thin
1 / 1
Bremelanotide is a synthetic melanocortin receptor agonist. Originally developed as a tanning agent, it is a metabolite of the compound MT-I and was later found to promote sexual function. Unlike most medications for erectile dysfunction in men targeting hemodynamic issues, it regulates libido by acting directly on melanocortin receptors in the central nervous system, particularly the hypothalamus. Its uniqueness lies in the fact that it is neither a hormone nor a nitric oxide pathway-based drug, and it has potential therapeutic effects in both men and women. The drug is administered via subcutaneous injection.
Bremelanotide is a synthetic melanocortin receptor agonist. Unlike typical erectile dysfunction medications that target blood flow, it regulates libido by acting directly on the central nervous system, specifically the hypothalamus.
No, its uniqueness lies in the fact that it is neither a hormone nor a nitric oxide pathway-based drug.
Currently, the drug is administered via subcutaneous injection. While intranasal formulations were explored, their development has progressed slowly.
In 2019, its branded drug Vyleesi was approved by the U.S. FDA specifically for the treatment of acquired and generalized sexual interest/arousal disorders in premenopausal women.
It has potential therapeutic effects for men, especially for male erectile dysfunction (for those who cannot use standard drugs like nitrates) and low libido. However, these applications are still under main research.
The most common side effects include nausea and flushing, along with a risk of increased blood pressure. Other challenges include the inconvenience of subcutaneous injections and market stigma surrounding sexual dysfunction.
